富康集團(tuán)創(chuàng)建于1993年，主要從事醫(yī)藥制劑、原料藥、熱敏材料等六大板塊八十多個(gè)產(chǎn)品的研發(fā)、生產(chǎn)和銷售，下轄富康制藥、瑞康精化、永康化學(xué)、博康制藥、內(nèi)蒙古欣皓醫(yī)藥等九大子公司，已成為20多家世界頂級(jí)制藥企業(yè)的重點(diǎn)供應(yīng)商。集團(tuán)公司2024年實(shí)現(xiàn)銷售收入約10億美元，爭(zhēng)取到2030年實(shí)現(xiàn)15億美元的銷售目標(biāo)。集團(tuán)公司先后通過了5次美國(guó)FDA認(rèn)證、5次歐盟認(rèn)證、2次世界衛(wèi)生組織，2次日本PMDA，2次澳大利亞TGA，一次巴西ANVISA，一次墨西哥COFEPRIS等國(guó)際權(quán)威質(zhì)量認(rèn)證，產(chǎn)品覆蓋國(guó)內(nèi)27個(gè)省市，暢銷美國(guó)、加拿大，俄羅斯，法國(guó)，西班牙，德國(guó)、英國(guó)，波蘭，捷克，意大利，日本，印度尼西亞，馬來(lái)西亞，墨西哥，巴西等80多個(gè)國(guó)家和地區(qū)。
主導(dǎo)產(chǎn)品雙胍（CAS NO.: 1115-70-4）、甲氧芐啶、奧美拉唑、氯氮平，間苯三酚，熱敏染料FB2C的產(chǎn)銷量居全球首位，國(guó)內(nèi)市場(chǎng)份額均在70%以上；新諾明、氯氮平，埃索鎂等品種產(chǎn)銷量居全國(guó)首位。雙胍緩釋片、吡格列酮雙胍片、間苯三酚注射液、泮托拉唑鈉腸溶片、復(fù)方新諾明片等19個(gè)制劑品種已上市銷售，具備注射液、凍干粉針劑、片劑、顆粒劑、膠囊劑等多種劑型以及配套原料藥的生產(chǎn)能力，建立起了以雙胍為代表的六條完整清晰全產(chǎn)業(yè)鏈。
先后躋身“中國(guó)醫(yī)藥工業(yè)百?gòu)?qiáng)”“中國(guó)醫(yī)藥企業(yè)國(guó)際化百?gòu)?qiáng)”“山東省‘十強(qiáng)’產(chǎn)業(yè)集群領(lǐng)軍企業(yè)”“濰坊市財(cái)稅貢獻(xiàn)50強(qiáng)企業(yè)”行列，獲得國(guó)家高新技術(shù)企業(yè)、國(guó)家知識(shí)產(chǎn)權(quán)優(yōu)勢(shì)企業(yè)、山東省引進(jìn)高層次人才重點(diǎn)支持企業(yè)、濰坊市突出貢獻(xiàn)企業(yè)等榮譽(yù)。
Founded in 1993, Fukang Group is primarily engaged in the R&D, production, and sales of over 80 products across six major sectors, including FDFs, APIs, thermosensitive new materials and so on. Fukang Group comprises nine subsidiaries, including Fukang Pharmaceutical Co., Ltd, Ruikang specialty Chemicals Co., Ltd, Yongkang Chemical Industry Co., Ltd, Bokang Pharmaceutical Co.,Ltd, and Inner Mongolia Xinhao Pharmaceutical Technology Co.,Ltd, and has become a key supplier to more than 20 of the world’s top pharmaceutical companies.
Fukang Group achieved sales revenue of approximately $1 billion In 2024 and aims to reach a sales target of $1.5 billion by 2030. The group has passed U.S. FDA certification(5 times), EU certification(5 times), WHO certification(2 times), Japan PMDA certification(2 times), Australia TGA certification(2 times), Brazil ANVISA certification(1 time), and Mexico COFEPRIS certification(1 time), among other international quality certifications. Its products are distributed across 27 provinces in China and exported to over 80 countries and regions, including the United States, Canada, Russia, France, Spain, Germany, the UK, Poland, the Czech Republic, Italy, Japan, Indonesia, Malaysia, Mexico, and Brazil.
The leading products—Metformin Hydrochloride, Trimethoprim, Omeprazole, Clozapine, Phloroglucinol, and FB2C—rank first globally in production and sales volume, each holding over 70% of the domestic market share. Other products—Sulfamethoxazole, Clozapine, and Esomeprazole Magnesium—also rank first in China in production and sales volume. Nineteen formulation products, including Metformin Hydrochloride Extended-release Tablets, Pioglitazone and Metformin Tablets, Phloroglucinol Injection, Pantoprazole Sodium Enteric-coated Tablets, and Compound Sulfamethoxazole Tablets, have been launched and are commercially available. The Group possesses production capabilities for various dosage forms, such as injections, lyophilized powder injections, tablets, granules, and capsules, along with supporting APIs. It has established six complete and well-defined industrial chains, with metformin as a representative example.
Fukang Group has been recognized among "China’s Top 100 Pharmaceutical Enterprises", "China’s Top 100 Internationalized Pharmaceutical Enterprises", "Shandong Province’s Top 10 Industrial Cluster Leading Enterprises" and "Weifang’s Top 50 Tax Contributors". It has also received honors such as National High-Tech Enterprise, National Intellectual Property Advantage Enterprise, Shandong Province Key Enterprise for High-Level Talent Recruitment, and Weifang Outstanding Contribution Enterprise.
